前列腺癌中氟-18前列腺特异性膜抗原-1007高摄取的不确定性骨病变:预测结局与预后的临床及PET/CT特征
回顾性分析105例前列腺癌患者158个18F-PSMA-1007 PET/CT上的不确定性骨病变,其中良性53个(33.5%)、恶性36个(22.8%)、不确定69个(43.7%);淋巴结转移、SUVmax和病变位置与病变良恶性相关并可预测病变判读,良性病变患者PSA和ALP下降最明显,可能提示预后更好。
要点
- 淋巴结转移、SUVmax和病变位置可能有助于判读前列腺癌患者的不确定性骨病变。
- 158个不确定性骨病变中良性33.5%、恶性22.8%、不确定43.7%。
- 良性不确定性骨病变患者PSA和ALP下降最明显,可能提示预后更好。
核心结论
- 淋巴结转移、SUVmax和病变位置可能有助于不确定性骨病变的判读;PSA和ALP水平快速下降可能提示良性不确定性骨病变患者预后更好。
研究设计与样本
- 回顾性分析连续接受PSMA PET/CT的患者,共105例(平均年龄±SD,72.1±8岁),识别出158个不确定性骨病变,以随访影像和临床处理判定良恶性。
关键影像表现/征象
- 158个不确定性骨病变中良性53个(33.5%)、恶性36个(22.8%)、不确定69个(43.7%)。
- 病变位置、SUVmax和淋巴结转移与不确定性骨病变的良恶性相关(分别为p=0.046、p<0.001和p<0.001)。
诊断标准与关键数值
- 回归分析提示淋巴结转移、SUVmax和病变位置可预测病变判读(分别为p<0.001、p=0.002和p=0.035)。
临床应用与阅片要点
- 判读前列腺癌患者18F-PSMA-1007 PET/CT上的不确定性骨病变时,可结合淋巴结转移、SUVmax和病变位置综合评估。
- 良性不确定性骨病变患者随访中PSA和ALP下降最明显,可能提示预后更好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To determine clinical and fluorine-18 prostate-specific membrane antigen-1007 (18F-PSMA-1007) integrated positron-emission tomography (PET)/computed tomography (CT) features that could be used to interpret indeterminate bone lesions (IBLs) and assess the prognosis of prostate cancer (PCa) in patients with IBLs.
MATERIALS AND METHODS: Consecutive patients who underwent PSMA PET/CT were analysed retrospectively. IBLs were identified as benign or malignant based on follow-up imaging and clinical management. Lesion- and patient-based assessments were performed to define features predictive of bone lesion results and determine clinical risk. Patients' prognosis was analysed based on clinical characteristics, including prostate-specific antigen (PSA) and alkaline phosphatase (ALP), respectively.
RESULTS: A total of 105 patients (mean age ± SD, 72.1 ± 8 years) were evaluated and 158 IBLs were identified. Fifty-three (33.5%), 36 (22.8%), and 69 (43.7%) IBLs were benign, malignant, and equivocal, respectively. Variables including location, maximum standard uptake value (SUVmax), and lymph node metastases (LNM) were related to the benignancy or malignancy of IBLs (p=0.046, p<0.001 and p<0.001, respectively). Regression analysis indicated that LNM, SUVmax, and location of IBLs could be predictors of lesion interpretation (p<0.001, p=0.002 and p=0.035). Patients with benign IBLs experienced the most considerable decreases in PSA and ALP levels.
CONCLUSIONS: LNM, SUVmax, and location may contribute to IBL interpretation. A rapid decrease in PSA and ALP levels might suggest a better prognosis for patients with benign IBLs.
引用
- Luo L, Wang Z, Wang X, et al. Fluorine-18 prostate-specific membrane antigen-1007-avid indeterminate bone lesions in prostate cancer: clinical and PET/CT features to predict outcomes and prognosis. Clin Radiol. 2024. PMID: 38216370. doi:10.1016/j.crad.2023.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。